Non-small cell lung cancer · line 3 · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	3
Track	aggressive
Linked regimen	`None`

ID	`IND-NSCLC-3L-OSI-FAILURE-AMI`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. 3L pathway for post-osimertinib EGFR NSCLC. Missing entity flag: dedicated REG-AMIVANTAMAB-CHEMO + REG-AMIVANTAMAB-LAZERTINIB-CHEMO — author in PROD-2.

Used By

Indication

IND-NSCLC-EGFR-MAINT-OSIMERTINIB - IND-NSCLC-EGFR-MAINT-OSIMERTINIB